Louis Sané
Vice President, Investor Relations
Replay available
Novavax, Inc. (NVAX) Q4 2025 Earnings Call
Novavax, Inc. (NASDAQ: NVAX) Q4 2025 earnings conference call, held 2026-02-26. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
John Jacobs
President and CEO
Elaine O'Hara
Chief Strategy Officer
Dr. Roxandra Draghia
Head of R&D
Jim Kelly
Chief Financial Officer and Treasurer
Roger Song
Analyst at Jefferies
Tom Schrader
Analyst at BTIG
Mayank Mamtami
Analyst at B. Riley Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Novavax, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.720 Good morning and welcome to Novavax fourth quarter and full year 2025 00:00:05.720 -- 00:00:11.108 financial results and operational highlights conference call. 00:00:11.108 -- 00:00:14.313 All participants will be in listen-only mode. 00:00:14.313 -- 00:00:19.241 Should you need assistance, please signal a conference specialist by pressing the star 00:00:19.241 -- 00:00:24.869 key followed by zero. After today's presentation, there will be an opportunity 00:00:24.869 -- 00:00:29.871 to ask questions. To ask a question, you may press star then the number one 00:00:29.871 -- 00:00:35.036 on your touchtone phone. To withdraw your question, please press star then the number 00:00:35.036 -- 00:00:39.622 one again. Please note, this event is being recorded. 00:00:39.622 -- 00:00:44.607 I would now like to turn the conference over to Louis Sané, Vice President, Investor 00:00:44.607 -- 00:00:47.888 Relations. Please go ahead. 00:00:48.671 -- 00:00:53.237 Good morning and thank you all for joining us today to discuss our fourth quarter and 00:00:53.237 -- 00:00:58.212 full year 2025 financial results and operational highlights. 00:00:58.212 -- 00:01:03.799 A press release announcing our results is available on our website at novavax.com, 00:01:03.799 -- 00:01:09.085 and an audio archive of this conference call will be available on our website later today. 00:01:09.085 -- 00:01:14.351 Please turn to slide two. Before we begin with prepared remarks, I need to remind 00:01:14.351 -- 00:01:19.197 you that this presentation includes forward-looking statements, including but not limited 00:01:19.197 -- 00:01:24.423 to statements related to Novavax's corporate strategy and operating plans, 00:01:24.423 -- 00:01:29.516 its strategic priorities, i...